GGrantIndex
← Leaderboards

Johannes Nowatzky

New York University School Of Medicine

$4,843,429
Attributed
$4,843,429
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $881.4K · FY201525
$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,843,429 · 3

By mechanism

R01$3,936,639 · 2
K08$906,790 · 1

Top collaborators

No co-investigators on record.

Most similar at New York University School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Mediating

Research focus

MediatingAutoimmunityT Cell ResponseTargeted TreatmentCellsInflammationUveitisAffectEffector T CellPublishingGenetic PolymorphismCd8-Positive T-LymphocytesGenetic EpistasisImmune ResponsePeptidesEndoplasmic ReticulumBlindnessHaplotypesGenome EditingHigh RiskCd8b1 GeneCrispr/Cas TechnologyImmune System DiseasesLiterature

Grant awards (16)

Modulation of immunodominance in HLA class I associated uveitides$292,988
R01 · FY2025 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$227,700
R01 · FY2025 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$196,050
R01 · FY2025 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$164,662
R01 · FY2025 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2024 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$423,750
R01 · FY2024 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2023 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$423,751
R01 · FY2023 · EY · contact PI
Modulation of immunodominance in HLA class I associated uveitides$457,650
R01 · FY2022 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet's eye disease$411,038
R01 · FY2022 · EY · contact PI
Unraveling the role of HLA-B51/ERAP1 in Behcet’s eye disease$423,750
R01 · FY2021 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2019 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2018 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2017 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2016 · EY · contact PI
Harnessing monoclonal Treg for the treatment of autoimmune uveitis$181,358
K08 · FY2015 · EY · contact PI